Biopharmaceuticals pipeline

Back

Since the start of Synthon’s biopharmaceutical activities in 2007, we have made significant progress with regard to development of products based on therapeutic proteins.

Our biopharmaceuticals project portfolio is well positioned to encompass multiple clinical-stage programs in 2016 as several drug candidates will enter the clinic in the years to come. Our portfolio is testimony to our focus and commitment to deliver medicines to treat medically complex and serious conditions such as cancer and autoimmune/neurodegenerative diseases.

Synthon Biopharmaceuticals pipeline
Synthon biopharmaceuticals pipeline 2017